Ahmedabad: China’s National Medical Products Administration has approved Desidustat tablets for treating renal anaemia in chronic kidney disease patients, announced Zydus Lifesciences. This has marked a regulatory milestone for the company’s innovative therapy in a major market. The drug is licensed to CMS International Development and Management Limited, a wholly owned subsidiary of China Medical System Holdings, under an exclusive agreement signed in 2020.Desidustat is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, or HIF-PHI, designed to treat anaemia in chronic kidney disease (CKD) patients. Zydus already markets the drug in India under the brand name Oxemia. The company said more than 100,000 CKD patients in India have been treated with the therapy since its 2022 launch.Zydus managing director Sharvil Patel said, “We are encouraged by the NMPA’s approval for marketing the drug in China.”
